Search

IntroductionOn March 11, 2020, the World Health Organization sounded the COVID-19 pandemic alarm. While efforts in the first few months focused on reducing the mortality of infected patients, there is increasing data on the effects of long-term infection (Post-COVID-19 condition). Among the different symptoms described after acute infection, those derived from autonomic dysfunction are especially frequent and limiting. ObjectiveTo conduct a narrative review synthesizing current evidence of the signs and symptoms of dysautonomia in patients diagnosed with COVID-19, together with a compilation of available treatment guidelines. ResultsAutonomic dysfunction associated with SARS-CoV-2 infection occurs at different temporal stages. Some of the proposed pathophysiological mechanisms include direct tissue damage, immune dysregulation, hormonal disturbances, elevated cytokine levels, and persistent low-grade infection. Acute autonomic dysfunction has a direct impact on the mortality risk, given its repercussions on the respiratory, cardiovascular, and neurological systems. Iatrogenic autonomic dysfunction is a side effect caused by the drugs used and/or admission to the intensive care unit. Finally, late dysautonomia occurs in 2.5% of patients with Post-COVID-19 condition. While orthostatic hypotension and neurally-mediated syncope should be considered, postural orthostatic tachycardia syndrome (POTS) appears to be the most common autonomic phenotype among these patients. A review of diagnostic and treatment guidelines focused on each type of dysautonomic condition was done. ConclusionSymptoms deriving from autonomic dysfunction involvement are common in those affected by COVID-19. These symptoms have a great impact on the quality of life both in the short and medium to long term. A better understanding of the pathophysiological mechanisms of Post-COVID manifestations that affect the autonomic nervous system, and targeted therapeutic management could help reduce the sequelae of COVID-19, especially if we act in the earliest phases of the disease.

In the framework of increasingly demanding legislation related to energy performance in buildings, the integration of photovoltaic systems in the building skin offers many possibilities. However, a continuous development of the building-integrated photovoltaics (BIPV) market in the next years necessarily demands the compliance with strict requirements in terms of design flexibility, aesthetics, durability, cost reduction, grid integration, testing standards and operation & maintenance. Within this context, a European consortium of 15 partners is developing the H2020 PVSITES project, “BIPV technologies and systems for large-scale market deployment”. The project will demonstrate an ambitious set of BIPV solutions, specially tailored to provide a comprehensive and robust answer to market demands. This paper focuses on some of the major results achieved at the time of writing. These include a detailed BIPV market and regulatory framework analysis and recommendations for the standardization of BIPV products. Novel developments of glazed crystalline silicon modules for BIPV integration are presented, with both opaque and see-thru variations. Also included are the selection of a battery technology best suited for inclusion in a custom-made building energy management system (BEMS), as well as a BIM-compatible software tool to assist the design of BIPV projects.

33rd European Photovoltaic Solar Energy Conference and Exhibition; 2882-2887, In the framework of increasingly demanding legislation related to energy performance in buildings, the integration of photovoltaic systems in the building skin offers many possibilities. However, a continuous development of the building-integrated photovoltaics (BIPV) market in the next years necessarily demands the compliance with strict requirements in terms of design flexibility, aesthetics, durability, cost reduction, grid integration, testing standards and operation & maintenance. Within this context, a European consortium of 15 partners is developing the H2020 PVSITES project, “BIPV technologies and systems for large-scale market deployment”. The project will demonstrate an ambitious set of BIPV solutions, specially tailored to provide a comprehensive and robust answer to market demands. This paper focuses on some of the major results achieved at the time of writing. These include a detailed BIPV market and regulatory framework analysis and recommendations for the standardization of BIPV products. Novel developments of glazed crystalline silicon modules for BIPV integration are presented, with both opaque and see-thru variations. Also included are the selection of a battery technology best suited for inclusion in a custom-made building energy management system (BEMS), as well as a BIM-compatible software tool to assist the design of BIPV projects.

Background: Safinamide modulates both dopaminergic and glutamatergic systems with positive effects on motor and non-motor symptoms of Parkinson's disease (PD). The drug utilization study SYNAPSES was designed to investigate the use of safinamide in routine clinical practice, as recommended by the European Medicines Agency. Objective: To describe the occurrence of adverse events in PD patients treated with safinamide in real-life conditions. Methods: The SYNAPSES trial is an observational, European, multicenter, retrospective-prospective cohort study. Patients were followed up to 12 months with analyses performed in the overall population and in patients aged >75 years, with relevant comorbidities and with psychiatric conditions. Results: Of the 1610 patients included, 82.4% were evaluable after 12 months with 25.1% of patients >75 years, 70.8% with relevant comorbidities and 42.4% with psychiatric conditions. During observation 45.8% patients experienced adverse events, 27.7% patients had adverse drug reactions and 9.2% patients had serious adverse events. The adverse events were those already described in the patients' information leaflet. The majority were mild or moderate and completely resolved and no differences were detected between the subgroup of patients. Clinically significant improvements were seen in the UPDRS motor score and in the UPDRS total score in >= 40% of patients, according to the criteria developed by Shulman et al. Conclusion: The SYNAPSES study confirms the good safety profile of safinamide even in special groups of patients. Motor complications and motor scores improved with clinically significant results in the UPDRS scale maintained in the long-term.